Maryville NURS 620 Exam 2 - Questions and Answers | A+
Graded 2025/26 Study Guide - 198 Questions and Answers
Already Graded A+ Premium Exam Tested And Verified
Subject Area Nursing - Advanced Pathophysiology and Pharmacology
Description This exam assesses advanced understanding of pathophysiological mechanisms
and pharmacotherapeutic management across major organ systems. It emphasizes
clinical reasoning, evidence-based practice, and integration of current guidelines
for the advanced practice nurse.
Expected Grade A+
Total Questions 198
Duration 3 hours
Learning Outcomes 1. Analyze complex pathophysiological alterations in cardiovascular, respiratory,
renal, endocrine, and neurological systems.
2. Evaluate pharmacodynamic and pharmacokinetic principles for safe prescribing
in diverse patient populations.
3. Synthesize evidence-based management strategies for acute and chronic
conditions.
Accreditation Designed to meet AACN Essentials and CCNE accreditation standards for
graduate nursing education.
Page 1
,1. A patient with chronic systolic heart failure (HFrEF) on optimized
guideline-directed medical therapy (GDMT) including sacubitril/valsartan,
beta-blocker, and mineralocorticoid receptor antagonist presents with worsening
dyspnea and edema despite adherence. Which pathophysiological mechanism best
explains the progression of heart failure in this context?
A. Sustained activation of the renin-angiotensin-aldosterone system (RAAS) leading to
myocardial fibrosis and volume overload.
B. Downregulation of beta-adrenergic receptors resulting in decreased contractile reserve.
C. Increased production of natriuretic peptides causing excessive diuresis and electrolyte
depletion.
D. Enhanced vagal tone leading to bradycardia and reduced cardiac output.
Answer: A. Sustained activation of the renin-angiotensin-aldosterone system
(RAAS) leading to myocardial fibrosis and volume overload.
Despite GDMT, RAAS activation can persist due to alternative pathways (e.g.,
chymase-mediated angiotensin II production) and aldosterone escape, promoting
fibrosis and fluid retention. Beta-receptor downregulation occurs but is less directly
tied to acute decompensation; natriuretic peptides are elevated but not excessive; vagal
tone is typically reduced in HF.
2. Which of the following best describes the mechanism by which loop diuretics can
induce ototoxicity, particularly with high doses or rapid administration?
A. Inhibition of the Na-K-2Cl cotransporter in the stria vascularis, disrupting the
endocochlear potential.
B. Direct toxic effect on hair cells mediated by reactive oxygen species generation.
C. Competitive antagonism of GABA receptors in the auditory cortex.
D. Reduction of cochlear blood flow due to systemic hypotension.
Answer: A. Inhibition of the Na-K-2Cl cotransporter in the stria vascularis,
disrupting the endocochlear potential.
Loop diuretics (e.g., furosemide) inhibit the Na-K-2Cl cotransporter in the stria
vascularis, which is essential for maintaining the high K+ concentration in endolymph
and the endocochlear potential. This disruption impairs hair cell function and can cause
transient or permanent hearing loss. ROS generation is secondary, not primary; GABA
antagonism is not relevant; hypotension may contribute but is not the direct
mechanism.
Page 2
,3. A patient with type 2 diabetes mellitus and stage 3 chronic kidney disease (eGFR
35 mL/min/1.73 m²) is being started on an SGLT2 inhibitor. Which of the following
adverse effects requires the most vigilant monitoring during the first few weeks of
therapy?
A. Hypoglycemia due to increased insulin sensitivity.
B. Acute kidney injury from reduced glomerular filtration.
C. Euglycemic diabetic ketoacidosis (DKA) with near-normal glucose levels.
D. Severe volume depletion causing orthostatic hypotension.
Answer: C. Euglycemic diabetic ketoacidosis (DKA) with near-normal glucose
levels.
SGLT2 inhibitors can cause euglycemic DKA, especially in patients with reduced
kidney function or those on insulin, due to enhanced ketone production and reduced
renal clearance. Hypoglycemia risk is low as they do not stimulate insulin secretion;
AKI is rare and typically occurs with volume depletion; volume depletion can occur but
is less insidious than euglycemic DKA.
4. A patient with severe sepsis and acute respiratory distress syndrome (ARDS) is
being managed with lung-protective ventilation. Which of the following ventilator
settings most directly reduces ventilator-induced lung injury through the mechanism
of limiting cyclic alveolar collapse and overdistension?
A. High positive end-expiratory pressure (PEEP) and low tidal volume (6 mL/kg predicted
body weight).
B. Low PEEP and high tidal volume (10 mL/kg).
C. High PEEP and high tidal volume (8 mL/kg).
D. Low PEEP and low tidal volume (4 mL/kg).
Answer: A. High positive end-expiratory pressure (PEEP) and low tidal volume (6
mL/kg predicted body weight).
The combination of high PEEP (to prevent end-expiratory alveolar collapse) and low
tidal volume (to avoid overdistension) minimizes atelectrauma and volutrauma, the key
components of ventilator-induced lung injury. Low PEEP allows cyclic collapse; high
tidal volume causes overdistension; excessively low tidal volume may cause hypercapnia
but is not standard.
Page 3
, 5. A patient with decompensated cirrhosis and ascites is started on spironolactone.
Which laboratory finding is most indicative of the desired therapeutic effect and also
serves as a marker for monitoring adverse effects?
A. Increase in serum sodium concentration.
B. Decrease in serum potassium concentration.
C. Increase in serum potassium concentration.
D. Decrease in serum creatinine concentration.
Answer: C. Increase in serum potassium concentration.
Spironolactone is a potassium-sparing diuretic that antagonizes aldosterone, leading to
increased sodium and water excretion while retaining potassium. A rise in serum
potassium (within normal range) indicates effective aldosterone blockade;
hyperkalemia is the main adverse effect. Sodium typically decreases due to dilution;
creatinine may improve but is not direct; potassium decreases with loop diuretics.
6. Which of the following best explains why angiotensin-converting enzyme
inhibitors (ACEIs) are preferred over angiotensin receptor blockers (ARBs) in
patients with heart failure with reduced ejection fraction (HFrEF) and a history of
myocardial infarction?
A. ACEIs provide greater reduction in afterload due to additional bradykinin potentiation.
B. ACEIs have a stronger evidence base for reducing mortality post-MI in HFrEF.
C. ARBs are contraindicated in patients with renal artery stenosis.
D. ACEIs are less likely to cause hyperkalemia than ARBs.
Answer: B. ACEIs have a stronger evidence base for reducing mortality post-MI in
HFrEF.
Landmark trials (e.g., SAVE, AIRE) demonstrated mortality benefit with ACEIs
post-MI in HFrEF. While ARBs are alternatives, the evidence for mortality reduction is
less robust in the immediate post-MI setting. Bradykinin potentiation may contribute
but is not the primary reason; both classes have similar renal effects; hyperkalemia risk
is comparable.
Page 4
Graded 2025/26 Study Guide - 198 Questions and Answers
Already Graded A+ Premium Exam Tested And Verified
Subject Area Nursing - Advanced Pathophysiology and Pharmacology
Description This exam assesses advanced understanding of pathophysiological mechanisms
and pharmacotherapeutic management across major organ systems. It emphasizes
clinical reasoning, evidence-based practice, and integration of current guidelines
for the advanced practice nurse.
Expected Grade A+
Total Questions 198
Duration 3 hours
Learning Outcomes 1. Analyze complex pathophysiological alterations in cardiovascular, respiratory,
renal, endocrine, and neurological systems.
2. Evaluate pharmacodynamic and pharmacokinetic principles for safe prescribing
in diverse patient populations.
3. Synthesize evidence-based management strategies for acute and chronic
conditions.
Accreditation Designed to meet AACN Essentials and CCNE accreditation standards for
graduate nursing education.
Page 1
,1. A patient with chronic systolic heart failure (HFrEF) on optimized
guideline-directed medical therapy (GDMT) including sacubitril/valsartan,
beta-blocker, and mineralocorticoid receptor antagonist presents with worsening
dyspnea and edema despite adherence. Which pathophysiological mechanism best
explains the progression of heart failure in this context?
A. Sustained activation of the renin-angiotensin-aldosterone system (RAAS) leading to
myocardial fibrosis and volume overload.
B. Downregulation of beta-adrenergic receptors resulting in decreased contractile reserve.
C. Increased production of natriuretic peptides causing excessive diuresis and electrolyte
depletion.
D. Enhanced vagal tone leading to bradycardia and reduced cardiac output.
Answer: A. Sustained activation of the renin-angiotensin-aldosterone system
(RAAS) leading to myocardial fibrosis and volume overload.
Despite GDMT, RAAS activation can persist due to alternative pathways (e.g.,
chymase-mediated angiotensin II production) and aldosterone escape, promoting
fibrosis and fluid retention. Beta-receptor downregulation occurs but is less directly
tied to acute decompensation; natriuretic peptides are elevated but not excessive; vagal
tone is typically reduced in HF.
2. Which of the following best describes the mechanism by which loop diuretics can
induce ototoxicity, particularly with high doses or rapid administration?
A. Inhibition of the Na-K-2Cl cotransporter in the stria vascularis, disrupting the
endocochlear potential.
B. Direct toxic effect on hair cells mediated by reactive oxygen species generation.
C. Competitive antagonism of GABA receptors in the auditory cortex.
D. Reduction of cochlear blood flow due to systemic hypotension.
Answer: A. Inhibition of the Na-K-2Cl cotransporter in the stria vascularis,
disrupting the endocochlear potential.
Loop diuretics (e.g., furosemide) inhibit the Na-K-2Cl cotransporter in the stria
vascularis, which is essential for maintaining the high K+ concentration in endolymph
and the endocochlear potential. This disruption impairs hair cell function and can cause
transient or permanent hearing loss. ROS generation is secondary, not primary; GABA
antagonism is not relevant; hypotension may contribute but is not the direct
mechanism.
Page 2
,3. A patient with type 2 diabetes mellitus and stage 3 chronic kidney disease (eGFR
35 mL/min/1.73 m²) is being started on an SGLT2 inhibitor. Which of the following
adverse effects requires the most vigilant monitoring during the first few weeks of
therapy?
A. Hypoglycemia due to increased insulin sensitivity.
B. Acute kidney injury from reduced glomerular filtration.
C. Euglycemic diabetic ketoacidosis (DKA) with near-normal glucose levels.
D. Severe volume depletion causing orthostatic hypotension.
Answer: C. Euglycemic diabetic ketoacidosis (DKA) with near-normal glucose
levels.
SGLT2 inhibitors can cause euglycemic DKA, especially in patients with reduced
kidney function or those on insulin, due to enhanced ketone production and reduced
renal clearance. Hypoglycemia risk is low as they do not stimulate insulin secretion;
AKI is rare and typically occurs with volume depletion; volume depletion can occur but
is less insidious than euglycemic DKA.
4. A patient with severe sepsis and acute respiratory distress syndrome (ARDS) is
being managed with lung-protective ventilation. Which of the following ventilator
settings most directly reduces ventilator-induced lung injury through the mechanism
of limiting cyclic alveolar collapse and overdistension?
A. High positive end-expiratory pressure (PEEP) and low tidal volume (6 mL/kg predicted
body weight).
B. Low PEEP and high tidal volume (10 mL/kg).
C. High PEEP and high tidal volume (8 mL/kg).
D. Low PEEP and low tidal volume (4 mL/kg).
Answer: A. High positive end-expiratory pressure (PEEP) and low tidal volume (6
mL/kg predicted body weight).
The combination of high PEEP (to prevent end-expiratory alveolar collapse) and low
tidal volume (to avoid overdistension) minimizes atelectrauma and volutrauma, the key
components of ventilator-induced lung injury. Low PEEP allows cyclic collapse; high
tidal volume causes overdistension; excessively low tidal volume may cause hypercapnia
but is not standard.
Page 3
, 5. A patient with decompensated cirrhosis and ascites is started on spironolactone.
Which laboratory finding is most indicative of the desired therapeutic effect and also
serves as a marker for monitoring adverse effects?
A. Increase in serum sodium concentration.
B. Decrease in serum potassium concentration.
C. Increase in serum potassium concentration.
D. Decrease in serum creatinine concentration.
Answer: C. Increase in serum potassium concentration.
Spironolactone is a potassium-sparing diuretic that antagonizes aldosterone, leading to
increased sodium and water excretion while retaining potassium. A rise in serum
potassium (within normal range) indicates effective aldosterone blockade;
hyperkalemia is the main adverse effect. Sodium typically decreases due to dilution;
creatinine may improve but is not direct; potassium decreases with loop diuretics.
6. Which of the following best explains why angiotensin-converting enzyme
inhibitors (ACEIs) are preferred over angiotensin receptor blockers (ARBs) in
patients with heart failure with reduced ejection fraction (HFrEF) and a history of
myocardial infarction?
A. ACEIs provide greater reduction in afterload due to additional bradykinin potentiation.
B. ACEIs have a stronger evidence base for reducing mortality post-MI in HFrEF.
C. ARBs are contraindicated in patients with renal artery stenosis.
D. ACEIs are less likely to cause hyperkalemia than ARBs.
Answer: B. ACEIs have a stronger evidence base for reducing mortality post-MI in
HFrEF.
Landmark trials (e.g., SAVE, AIRE) demonstrated mortality benefit with ACEIs
post-MI in HFrEF. While ARBs are alternatives, the evidence for mortality reduction is
less robust in the immediate post-MI setting. Bradykinin potentiation may contribute
but is not the primary reason; both classes have similar renal effects; hyperkalemia risk
is comparable.
Page 4
